senseneres: WHAT SHOULD WE DO WITH BIOSAFETY IN THE PHILIPPINES?

WHAT SHOULD WE DO WITH BIOSAFETY IN THE PHILIPPINES?

The short answer: we need to do more, and do it now. In fact, one might say that aside from a few frameworks, we’re not doing enough.

Here’s my take — drawing from an article that shows how the U.S. is wrestling with biosafety oversight — and applying it to our Philippine context (where the frameworks exist, but the practice often lags).

What’s already in place

We in the Philippines have some laws and executive orders. For example:

Executive Order No. 514 (2006) establishes the National Biosafety Framework (NBF) and strengthens the National Committee on Biosafety of the Philippines (NCBP).
The NBF is meant to “apply to the development, adoption and implementation of all biosafety policies, measures and guidelines … concerning the research, development, handling and use, transboundary movement, release into the environment and management of regulated articles.”
The Department of Science and Technology–NCBP website notes that the Philippines was one of the first in Southeast Asia to adopt a national biosafety framework.

So yes – we have regulations and institutions.

So … what’s missing? Why am I worried?

Because:

The frameworks are narrow. The NBF and guidelines focus heavily on genetically modified organisms (GMOs), biotechnology, and environmental release. They less explicitly cover lab-accidents, pathogen research, or the full lifecycle of risks.
We lack comprehensive legislation. One recent review observes: “Despite decades of biotech presence and policy activity, the Philippines has yet to enact a national biosafety law.”
Oversight tends to be front-loaded (at proposal stage) rather than continuous through research, deployment, dissemination. The U.S. article highlighted how checking only at the start fails to catch emerging risks mid-project or downstream when results are published.
We need integration across sectors. Biosafety isn’t just about health (via the Department of Health / DOH) or agriculture (via the Department of Agriculture / DA) — it spans environment, science, industry, research labs, data, digital biology. The Philippine policy history itself admitted the need to add agencies like the Department of Environment and Natural Resources (DENR), the Department of Trade and Industry (DTI) and the Department of the Interior and Local Government (DILG).

In other words: the regulatory structure is fragmented. The article argues that this kind of patchwork leaves gaps, creates confusion, and reduces public trust. The Philippines appears to face similar issues.

So what should we do?

Here are proposals (with commentary):

Elevate biosafety as a national, coordinated priority

We need a central coordinating body (or upgrade an existing one) which oversees biosafety in all sectors — not just biotech or GMOs, but labs, pathogens, digital biology, synthetic biology. The U.S. article calls this a “National Biosafety and Biosecurity Agency” (NBBA). We should consider a Philippine variant.
This body should ensure multi-agency coordination — DOST, DOH, DA, DENR, DILG, DTI, possibly local government units (LGUs).

Move from proposal-stage oversight to lifecycle oversight

Don’t stop at “before research starts”. Oversight needs to continue during research (“bench level”), after results (“publication/dissemination”), and into deployment or commercialization.
Training, regular audits, incident reporting systems are needed so that early signs of risk are flagged.

Close legislative and institutional gaps

Enact a dedicated biosafety law that covers all high-consequence biological research, lab safety, dual-use research of concern, digital bio data. Administrative orders are not enough.
Provide resources: budgets, staffed agencies, training, and monitoring mechanisms — as EO 514 mandates funding via DOST, DENR, DA, DOH.

Engage the broader community and ensure public trust

Biosafety isn’t just a researcher’s problem. The public expects transparency, accountability, and clarity.
Local communities, LGUs, and civil society should have roles in decision-making and monitoring.
Incident reporting should be anonymous, transparent, and lead to learning — not blame-only.

Strengthen capacity and awareness

Train and certify biosafety professionals. The Philippine system needs more qualified biosafety officers, institutional biosafety committees (IBCs) and strong practices.
Create guidelines for labs beyond GMO work: infectious disease labs, emerging biotech platforms. For instance, during COVID-19 the Research Institute for Tropical Medicine (RITM) issued interim biosafety guidelines for SARS-CoV-2.

Align with global developments and anticipate emerging risks

Biological risks now include digital data (DNA sequences), synthetic biology, cross-border movement of pathogens, etc. Oversight frameworks need to be adaptive. The U.S. article warns: “biology isn’t just physical anymore: DNA can be digitized”.
The Philippines must update its definitions, expand the scope of frameworks beyond just GMOs. As one study noted, the current definition is still limited to modern biotechnology, exotic species and environment.

Who, aside from DOH, should be involved in biosafety?

To make this real, the following must be included:

DOST (Department of Science and Technology) — for research, science policy.
DA (Department of Agriculture) — for biotech in agriculture, GM crops, animal/plant pathogens.
DENR (Department of Environment and Natural Resources) — ecosystem impacts, release into the environment.
DILG (Department of the Interior & Local Government) / LGUs — for local laboratories, local outbreak response, community oversight.
DTI (Department of Trade & Industry) — for commercial biotech, industry regulation, imports/exports of regulated organisms.
Academic and research institutions — they host labs, generate research, need institutional biosafety committees.
Private sector biotech/biopharma labs — they must be regulated and monitored.
Civil society and community organizations — for public engagement, transparency, ethical review.
Indigenous peoples’ representatives (especially where biological materials or environment are involved).
International cooperation partners — for transboundary biosafety concerns, data sharing, standards.

If I were to summarize: we in the Philippines are not fully prepared. We have the regulatory skeleton, but the flesh — coordination, implementation, capacity, lifecycle oversight, public trust — is weaker than it should be given today’s risks. COVID-19 taught us that biological risk is no longer hypothetical.

So what we should do is clear: make biosafety real, holistic, and proactive. Let’s move from “we’ll react if something goes wrong” to “we will prevent things from going wrong in the first place, together”. Because if we don’t, we risk not only research accidents, but public health, environmental, economic and national security consequences.

We should ask: Are our laws adequate? Are our labs safe? Is oversight continuous? Do communities trust the system? Is government coordination effective? If we can’t answer “yes” confidently, then we must act — and act fast.

That’s what should be done with biosafety in the Philippines.

www.facebook.com/ike.seneres iseneres@yahoo.com

senseneres.blogspot.com 09088877292/05-11-2026